Anti-CLDN6/anti-CD3 bispecific Therapy(Integral Molecular)

N/A

Report date: 2024/05/14 17:36:30

Base Information

Drug NameAnti-CLDN6/anti-CD3 bispecific Therapy(Integral Molecular)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsClaudin 6 modulators
TargetsT cell surface glycoprotein CD3Claudin 6
Therapy Area/IndicationsEndometrial NeoplasmsOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIntegral Molecular Inc
China Registration ClassN/A

Develop Information

Active CompaniesIntegral Molecular Inc
Inactive CompaniesN/A
Active IndicationsEndometrial NeoplasmsOvarian Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A